•
Sep 30, 2024
Ironwood Pharmaceuticals Q3 2024 Earnings Report
Reported third quarter results with LINZESS prescription demand growth and progress on apraglutide NDA submission.
Key Takeaways
Ironwood Pharmaceuticals reported its third quarter 2024 results, highlighting a 13% year-over-year growth in LINZESS prescription demand. The company is maintaining its full year financial guidance and is on track to complete the apraglutide NDA submission in Q1 2025.
LINZESS prescription demand grew by 13% year-over-year.
LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year.
The company remains on track to complete apraglutide NDA submission in Q1 2025.
Full year 2024 financial guidance is maintained despite pricing headwinds.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Forward Guidance
Ironwood Pharmaceuticals is maintaining its full year 2024 financial guidance and expects to complete the apraglutide NDA submission in the first quarter of 2025.
Positive Outlook
- Continued growth in LINZESS prescription demand.
- On track to complete apraglutide NDA submission in Q1 2025.
- Focus on getting apraglutide to market as soon as possible.
- Belief that apraglutide would be the drug of choice for SBS patients dependent on PS, if approved.
- Maintaining full year financial guidance.
Challenges Ahead
- LINZESS faced pricing headwinds throughout 2024.
- Uncertainty related to pricing and reimbursement policies in the U.S.
- Risk of competition from new products.
- Challenges in partnering with other companies to develop and commercialize products.
- Potential adverse effects from healthcare reform and other governmental and private payor initiatives.